American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103

Brachytherapy

Volumn 6, Issue 1, 2007, Pages 34-37

  Rivard, Mark J ^a   Butler, Wayne M ^b   Devlin, Phillip M ^c   Hayes Jr , John K ^d   Hearn, Robert A ^e   Lief, Eugene P ^f   Meigooni, Ali S ^g   Merrick, Gregory S ^b   Williamson, Jeffrey F ^h  

^a TUFTS MEDICAL CENTER   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Gamma West   (United States)

^e Theragenics Corporation   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

103Pd; 125I; ABS guidelines; Dosimetry; Prescription; Prostate brachytherapy

Indexed keywords

IODINE 125; PALLADIUM 103;

ARTICLE; BRACHYTHERAPY; CONSENSUS; DOSIMETRY; IMPLANT; PRIORITY JOURNAL;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PRACTICE GUIDELINES; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE; SOCIETIES, MEDICAL;

EID: 33846566218     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2006.11.001     Document Type: Article

References (22)

1. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
2. 103palladium brachytherapy. Int J Radiat Oncol Biol Phys 47 (2000) 273-275
3. Rivard M.J., Coursey B.M., DeWerd L.A., et al. Update of AAPM task group No. 43 report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 31 (2004) 633-674
4. 125I Interstitial brachytherapy. Med Phys 32 (2005) 1424-1439
5. 103Pd interstitial source calibration and dosimetry: Implications for dose specification and prescription (AAPM Report No. 69). Med Phys 27 (2000) 634-642
6. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 22 (1995) 209-234
7. Williamson J.F., Coursey B.M., DeWerd L.A., et al. Guidance to users of Nycomed Amersham and North American Scientific, Inc. I-125 Interstitial Sources: Dosimetry and calibration changes: Recommendation of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry. Med Phys 26 (1999) 570-573
8. 103Pd brachytherapy seeds. J Res Natl Inst Stand Technol 108 (2003) 337-358
9. 103Pd seeds with air kerma strength calibration based upon a primary national standard. Med Phys 27 (2000) 655-658
10. Merrick G.S., Wallner K.E., and Butler W.M. Minimizing prostate brachytherapy-related morbidity. Urology 62 (2003) 786-792
11. Stock R.G., Kao J., and Stone N.N. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165 (2001) 436-439
12. Wallner K., Roy J., and Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 32 (1995) 465-471
13. Merrick G.S., Butler W.M., Waller K.E., et al. Variability of prostate preimplant dosimetry: A multi-institutional analysis. Brachytherapy 4 (2005) 241-251
14. 125Iodine brachytherapy of prostate cancer. J Urol 173 (2005) 803-807
15. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
16. 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
17. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
18. Potters L., Morgenstern, Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
19. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: A 12-year experience from a single group practice. Brachytherapy 4 (2005) 34-44
20. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: Influence of prostatic acid phosphatase. Cancer 97 (2003) 979-983
21. Nath R., Anderson L.L., Meli J.A., et al. Code of practice for brachytherapy physics: Report of the AAPM Radiation Therapy Committee Task Group No. 56. Med Phys 24 (1997) 1557-1598
22. 60Co therapy level beams, and the transfer to the AAPM accredited dosimetry calibration laboratories. Med Phys 33 (2006) 1074-1077